Summary
Fidji Simo, a former OpenAI executive, agrees with Dario Amodei on the necessity for AI companies to demonstrate genuine medical advancements rather than just marketing. Simo highlights biological data as a significant challenge for AI-based treatments, noting that cancer research benefits from extensive existing datasets.